Investors

Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.

Nasdaq Stockholm

Price

Change

Latest investor news

May 15, 2026

Oncopeptalks: Q1 report

Investor

May 13, 2026

Redeye interviews Oncopeptides CEO Sofia Heigis

Investor

May 8, 2026

Launching: Oncopeptalks as a podcast

Investor

March 23, 2026

CEO Sofia Heigis presented at Redeye event Commercialization in Life Science

Investor

March 20, 2026

Sofia Heigis presented and interviewed at Stockholm Corporate Finance Life Science Days

Investor

March 11, 2026

CEO Sofia Heigis presents Oncopeptides at Aktiespararna

Investor

March 5, 2026

Biostock: presentation and interview with Sofia Heigis

Investor

February 20, 2026

Oncopeptides CEO Sofia Heigis interviewed by Redeye about Q4 and the new share issue

Investor

May 21, 2026

Bulletin from the Annual General Meeting in Oncopeptides

Regulatory

May 20, 2026

Study confirms use of Pepaxti in a broader population, with strong data in the 50% of RRMM patients that suffer from reduced kidney function

May 19, 2026

Oncopeptides receives formal approval from Norwegian authorities to initiate Window-of-Opportunity study in glioblastoma

May 13, 2026

COMy: New clinical and real-world evidence for Pepaxti demonstrating strong data and expanded positioning

No upcoming events

Investor Relations Contact

David Augustsson, MSc

Director of IR and Communications

ir@oncopeptides.com

+46 762 29 38 68

Investors

Latest investor news

Investor Relations Contact

More investor information

The share

General Meeting

Financial Reports

Financial Calendar